QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:ORIC

ORIC Pharmaceuticals (ORIC) Stock Price, News & Analysis

$12.74
+0.99 (+8.43%)
(As of 02/29/2024 ET)
Today's Range
$11.86
$14.70
50-Day Range
$8.04
$12.66
52-Week Range
$4.09
$14.70
Volume
2.86 million shs
Average Volume
505,253 shs
Market Capitalization
$858.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.86

ORIC Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
24.5% Upside
$15.86 Price Target
Short Interest
Bearish
9.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
0.60mentions of ORIC Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$339,288 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.96) to ($2.02) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.79 out of 5 stars

Medical Sector

466th out of 958 stocks

Pharmaceutical Preparations Industry

217th out of 447 stocks


ORIC stock logo

About ORIC Pharmaceuticals Stock (NASDAQ:ORIC)

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Stock Price History

ORIC Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up to $10.12
ORIC May 2024 5.000 call
ORIC Mar 2024 25.000 call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares
Final Boarding Call: 3 Stocks Set for a Sky-High Surge
See More Headlines
Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/29/2024
Next Earnings (Estimated)
3/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORIC
Fax
N/A
Employees
93
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.86
High Stock Price Target
$27.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+21.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-89,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.62 per share

Miscellaneous

Free Float
63,769,000
Market Cap
$882.55 million
Optionable
Optionable
Beta
1.00
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Richard A. Heyman Ph.D. (Age 67)
    Co-Founder, Independent Chairman & Member of Scientific Advisory Board
    Comp: $93k
  • Dr. Jacob M. Chacko M.B.A. (Age 45)
    M.D., President, CEO & Director
    Comp: $921.32k
  • Mr. Dominic G. Piscitelli CPA (Age 49)
    M.B.A., Chief Financial Officer
    Comp: $636.91k
  • Dr. Pratik S. Multani M.D. (Age 57)
    M.S., Chief Medical Officer
    Comp: $686.88k
  • Dr. Charles L. Sawyers B.A. (Age 65)
    M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Scott W. Lowe Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Lori Sickels Friedman Ph.D. (Age 60)
    Chief Scientific Officer
  • Dr. Christian V. Kuhlen Esq. (Age 51)
    J.D., M.D., General Counsel
  • Mr. Daniel Iazzetti
    VP & Head of People
  • Dr. Edna Chow Maneval (Age 64)
    Senior Vice President of Clinical Development














ORIC Stock Analysis - Frequently Asked Questions

Should I buy or sell ORIC Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ORIC shares.
View ORIC analyst ratings
or view top-rated stocks.

What is ORIC Pharmaceuticals' stock price target for 2024?

8 brokers have issued 1 year target prices for ORIC Pharmaceuticals' stock. Their ORIC share price targets range from $12.00 to $27.00. On average, they predict the company's stock price to reach $15.86 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price.
View analysts price targets for ORIC
or view top-rated stocks among Wall Street analysts.

How have ORIC shares performed in 2024?

ORIC Pharmaceuticals' stock was trading at $9.20 at the beginning of the year. Since then, ORIC stock has increased by 38.5% and is now trading at $12.74.
View the best growth stocks for 2024 here
.

When is ORIC Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ORIC earnings forecast
.

How were ORIC Pharmaceuticals' earnings last quarter?

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.11.

What other stocks do shareholders of ORIC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG).

When did ORIC Pharmaceuticals IPO?

(ORIC) raised $75 million in an initial public offering on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO.

Who are ORIC Pharmaceuticals' major shareholders?

ORIC Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.34%), Vivo Capital LLC (1.26%), Price T Rowe Associates Inc. MD (0.97%), Price T Rowe Associates Inc. MD (0.97%), Point72 Asset Management L.P. (0.77%) and Northern Trust Corp (0.52%). Insiders that own company stock include Carl L Gordon, Dominic Piscitelli, Jacob Chacko, Orbimed Advisors Llc, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller.
View institutional ownership trends
.

How do I buy shares of ORIC Pharmaceuticals?

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORIC) was last updated on 2/29/2024 by MarketBeat.com Staff